Generate Biomedicines raises $370M Series B with a focus on protein-based drugs

18th November 2021 – Featured on Techcrunch.com – The drug development space is continuing to attract more and more investment. On Thursday, another major player, Generate Biomedicines, announced a $370 million Series B round.

Generate Biomedicines is touting a platform-based approach to drug development, but with its own spin: a focus on proteins.